Abstract
Acquired thrombotic thrombocytopenic purpura (aTTP) is an acute life-threatening disease where mortality rates are critical outcomes. Caplacizumab has been included as part of the treatment of aTTP along with plasma exchange and immunosuppression. The objective was to determine health outcomes and costs avoided in the treatment of an aTTP episode with caplacizumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
